GlassScriptPhysician profile
Paige E King
NPI 1386175313
$10,282.72
in general payments reported to CMS, 2019-2025
27 companies · $79.53 in 2025
The $79.53 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.50 · 2020: $12.73 · 2021: $152 · 2022: $352 · 2023: $9,348 · 2024: $325 · 2025: $79.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,000 · Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,000.00 |
| Food and Beverage | $752.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,000.00 | 2023 | Davinci Xi |
| Abbvie INC. | $205.02 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $146.25 | 2023-2024 | |
| Organon LLC | $141.00 | 2021-2024 | Nexplanon |
| Hologic Sales and Service, LLC | $100.09 | 2023-2024 | Aptima, Myosure Tissue Removal Device |
| Agile Therapeutics, INC. | $70.29 | 2021-2024 | Twirla |
| Shield Therapeutics INC | $63.47 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $62.74 | 2023-2024 | |
| Astellas Pharma US INC | $58.23 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $55.10 | 2023-2025 | Myfembree |
| Boston Scientific Corporation | $42.28 | 2022 | |
| Coopersurgical, INC. | $37.34 | 2024 | Paragard T 380a |
| Therapeuticsmd, INC. | $35.36 | 2021 | |
| Millicent US INC | $34.76 | 2024-2025 | Intrarosa, Femring |
| Evofem Biosciences, INC. | $27.96 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.57 | 2023 | Cologuard Collection Kit |
| Myovant Sciences INC. | $21.46 | 2022 | |
| Biogen, INC. | $20.61 | 2025 | Zurzuvae |
| Pfizer INC. | $20.34 | 2022 | |
| Novo Nordisk INC | $17.91 | 2022 | |
| Lilly USA, LLC | $15.67 | 2021 | |
| Meditrina | $14.89 | 2023 | |
| Scynexis, INC. | $13.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.88 | 2022 | |
| Tesaro, INC. | $13.50 | 2019 | |
| Avion Pharmaceuticals | $13.29 | 2021 | |
| Clovis Oncology, INC. | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.